Xiaoping Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xiaoping Chen has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Lingling Zhu
Department of Brain Protection, Institute of Basic Medical Sciences, Beijing, PR China
2 shared publications- Xiang Li
Beijing Life Science Academy, Beijing 102209, China
2 shared publications Alexander C. Castillo
1 shared publicationBejoy Thomas
1 shared publicationBo Long
1 shared publicationHongmei Ye
State Key Laboratory of Space Medicine Fundamentals and Application, Astronaut Research and Training Center of China, Beijing, People’s Republic of China
1 shared publication
Latest Publications
- 1 May 2013
- Published by Wolters Kluwer Health in Hypertension
- Vol. 61 (5) , 1008-1013
Nebivolol Induces Distinct Changes in Profibrosis MicroRNA Expression Compared With Atenolol, in Salt-Sensitive Hypertensive Rats
Nebivolol is a selective β1-blocker with nitric oxide–enhancing effects. MicroRNAs are small noncoding RNA molecules that downregulate gene expression. We compared the effects of nebivolol and atenolol, a first generation β1-selective blocker, on left ventricular hypertrophy, fibrosis, and function and microRNA expression in a rodent model of hypertension. Dahl salt-sensitive rats received either low-salt chow (control) or AIN-76A high-salt (8% NaCl) diet and randomized to vehicle (high-salt), nebivolol (20 mg/kg per day), or atenolol (50 mg/kg per day) for 8 weeks. High-salt induced left ventricular hypertrophy and fibrosis and decreased the expression of miR-27a, -29a, and -133a. Nebovolol attenuated deterioration of left ventricular systolic function, remodeling, and fibrosis more than atenolol, despite similar effects on heart rate and blood pressure. Nebivolol, but not atenolol, prevented the decrease in miR-27a and -29a induced by high-salt. Nebivolol and atenolol equally attenuated the decrease in miR-133a. In vitro overexpression of miR-27a,-29a, and -133a inhibited cardiomyocyte hypertrophy and reduced collagen expression. Both miR-27a and -29a target Sp1, and miR-133a targets Cdc42. Pharmacological inhibition of Sp1 and Cdc42 decreased myocardial fibrosis and hypertrophy. Our data support a differential microRNAs expression profile in salt-induced hypertension. Nebivolol substantially attenuated cardiac remodeling, hypertrophy, and fibrosis more than atenolol. These effects are related to attenuation of the hypertension-induced decrease in miR-27a and -29a (with a subsequent decrease in Sp1 expression) and miR-133a (with a subsequent decrease in Cdc42).
- 1 May 2013
- Published by Wolters Kluwer Health in Hypertension
- Vol. 61 (5) , 1008-1013
Nebivolol Induces Distinct Changes in Profibrosis MicroRNA Expression Compared With Atenolol, in Salt-Sensitive Hypertensive Rats
Nebivolol is a selective β1-blocker with nitric oxide–enhancing effects. MicroRNAs are small noncoding RNA molecules that downregulate gene expression. We compared the effects of nebivolol and atenolol, a first generation β1-selective blocker, on left ventricular hypertrophy, fibrosis, and function and microRNA expression in a rodent model of hypertension. Dahl salt-sensitive rats received either low-salt chow (control) or AIN-76A high-salt (8% NaCl) diet and randomized to vehicle (high-salt), nebivolol (20 mg/kg per day), or atenolol (50 mg/kg per day) for 8 weeks. High-salt induced left ventricular hypertrophy and fibrosis and decreased the expression of miR-27a, -29a, and -133a. Nebovolol attenuated deterioration of left ventricular systolic function, remodeling, and fibrosis more than atenolol, despite similar effects on heart rate and blood pressure. Nebivolol, but not atenolol, prevented the decrease in miR-27a and -29a induced by high-salt. Nebivolol and atenolol equally attenuated the decrease in miR-133a. In vitro overexpression of miR-27a,-29a, and -133a inhibited cardiomyocyte hypertrophy and reduced collagen expression. Both miR-27a and -29a target Sp1, and miR-133a targets Cdc42. Pharmacological inhibition of Sp1 and Cdc42 decreased myocardial fibrosis and hypertrophy. Our data support a differential microRNAs expression profile in salt-induced hypertension. Nebivolol substantially attenuated cardiac remodeling, hypertrophy, and fibrosis more than atenolol. These effects are related to attenuation of the hypertension-induced decrease in miR-27a and -29a (with a subsequent decrease in Sp1 expression) and miR-133a (with a subsequent decrease in Cdc42).
- Open Access
- 21 November 2011
- Published by Wiley in Experimental Physiology
- Vol. 97 (2) , 257-264
Extracellular signal‐regulated kinase 1/2 mitogen‐activated protein kinase pathway is involved in inhibition of myogenic differentiation of myoblasts by hypoxia
Oxygen conditions influence a variety of biological processes of cells, including alterations in cellular growth, survival and differentiation. However, there have been few studies on the effects of hypoxia on proliferation and differentiation of myoblasts. In this study, we observed the effects of hypoxia (3% O2) on myogenic differentiation of C2C12 myoblasts and sought a possible mechanism involved in the regulation of myogenic differentiation of myoblasts by hypoxia. The expression of myosin heavy chain was detected by immunocytochemistry staining and Western blot analysis. The expression of muscle regulatory transcription factors was examined by RT‐PCR analysis and Western blot analysis. The activity of extracellular signal‐regulated kinases (ERK1/2) was investigated by forced expression of mitogen‐activated protein kinase kinase 1 (MEK1(E)) and using Western blot analysis. We found that hypoxia inhibited myogenic differentiation of myoblasts. The expression of muscle regulatory transcription factors was downregulated by hypoxia in C2C12 myoblasts. During the inhibition of myogenic differentiation by hypoxia, ERK1/2 activation was suppressed, and increasing ERK1/2 activity by forced expression of MEK1(E) could partly reverse the inhibition of myogenic differentiation by hypoxia. These results suggest that the ERK1/2–mitogen‐activated protein kinase pathway might be a possible mechanism involved in the inhibition of myogenic differentiation by hypoxia.
- 21 November 2011
- Published by Wiley in Experimental Physiology
- Vol. 97 (2) , 257-264
Open AccessExtracellular signal‐regulated kinase 1/2 mitogen‐activated protein kinase pathway is involved in inhibition of myogenic differentiation of myoblasts by hypoxia
Oxygen conditions influence a variety of biological processes of cells, including alterations in cellular growth, survival and differentiation. However, there have been few studies on the effects of hypoxia on proliferation and differentiation of myoblasts. In this study, we observed the effects of hypoxia (3% O2) on myogenic differentiation of C2C12 myoblasts and sought a possible mechanism involved in the regulation of myogenic differentiation of myoblasts by hypoxia. The expression of myosin heavy chain was detected by immunocytochemistry staining and Western blot analysis. The expression of muscle regulatory transcription factors was examined by RT‐PCR analysis and Western blot analysis. The activity of extracellular signal‐regulated kinases (ERK1/2) was investigated by forced expression of mitogen‐activated protein kinase kinase 1 (MEK1(E)) and using Western blot analysis. We found that hypoxia inhibited myogenic differentiation of myoblasts. The expression of muscle regulatory transcription factors was downregulated by hypoxia in C2C12 myoblasts. During the inhibition of myogenic differentiation by hypoxia, ERK1/2 activation was suppressed, and increasing ERK1/2 activity by forced expression of MEK1(E) could partly reverse the inhibition of myogenic differentiation by hypoxia. These results suggest that the ERK1/2–mitogen‐activated protein kinase pathway might be a possible mechanism involved in the inhibition of myogenic differentiation by hypoxia.
- 1 January 2007
- Published by Elsevier in Medical Hypotheses
- Vol. 69 (3) , 629-636
Effects of hypoxia on proliferation and differentiation of myoblasts
- 1 January 2007
- Published by Elsevier in Medical Hypotheses
- Vol. 69 (3) , 629-636
Effects of hypoxia on proliferation and differentiation of myoblasts